The cell research journal GV-971 treats Alzheimer's disease

week ago (July 6), Rao Yi, a professor at Peking University, published an article entitled
("The author's previous research omissions to be corrected") in
.
article on
Shanghai Drug Research Institute Geng Meiyu team last September on Alzheimer's disease domestic new drug GV-971 research paper, mainly raised two questions. These include why Geng didn't cite his previous findings and why the GV-971 has so many targets.July 13, Geng Meiyu's team responded to questions raised above in Cell Research.In a cover article published on September 6, 2019, Cell Research identified a oligosaccharide called sodium oligoglyceride (the main component of GV-971) that inhibits the progression of Alzheimer's disease by reshaping the gut bacteribus and suppressing bacterial amino acid-type neuroinvestillation in the gut.between Mr. Rao and Mr. Geng revolved around the cover story.
two main questions from Rao Yi's article and the corresponding response of Geng Meiyu's team.Geng Meiyu has previously published 12 papers related to GV971, including in vitro and in vitro studies. Seven of them are original research papers on GV971, and the rest are reviews or related papers.
but none of these papers is quoted in this paper.don't think these 12 papers are suitable for citation. Because their relevance to the study is limited. In
12 papers:
4 are review articles summarizing the potential and rationale of sugars in the treatment of Alzheimer's disease. None of these reviews focuses on GV-971.
5 were only as far away from the study: 3 studied the effects of GV-971 on β amyloid protein (A-beta, known as Alzheimer's disease-related proteins) aggregation and neuronal toxicity, and A-beta-induced astrogens The memory disorders induced by protocytocytostic cell -alkali, one attempt to identify GV-971 binding proteins in-body, and another preliminary study of gene expression changes caused by GV-971 in A-beta-dependent mouse models.
The remaining three: one focuses on the chemical synthesis of GV-971 derivatives, not on GV-971 itself; one is a peer-reviewed summary of GV-971 research that was not published at the time; and one examines the potential effects of GV-971 on Parkinson's disease, unlike Alzheimer's disease.Previous research by The Geng Meiyu team claims that GV-971 can bind directly to A beta while protecting the nervous system from
A beta poisoning In that study last year, GV971 also indirectly inhibited the progression of Alzheimer's disease by regulating gut microbes and inflammation.
these effects are significantly different in terms of drug targets, location of effective locations, and treatment mechanisms.
"Although the presence of different targets usually implies side effects, the authors claim that all targets and effects of GV971 can help alleviate Alzheimer's disease." In my own research on the history of biomedical research at home and abroad, I have never encountered a drug that can treat or alleviate a disease with so many targets. "" we do not agree with this assessment. In
, it is not uncommon for the market to sell drugs to achieve the desired therapeutic effect by targeting multiple pathways.
Taking metformin, the most widely used oral type 2 diabetes drug, as an example, it controls blood sugar through different mechanisms in a variety of tissues, including reducing liver glucose production, reducing intestinal glucose absorption, and improving the absorption and utilization of glucose in the outer tissue.
although it has long been thought to be an inhibitor of mitochondrial complex 1 and an activator of AMPK, there has been growing evidence recently that changes in the gut microbiome can also help treat type 2 diabetes.a decade of efforts to better understand the molecular mechanisms and therapeutic uses of GV-971. To date, we have found a number of mechanisms that work together to promote the therapeutic effect of GV-971 in alzheimer's patients.
effects of GV-971 on intestinal bacteria and associated neuro-inflammation may be one of the most important aspects. We have also accumulated a large amount of data that supports the effects of GV-971 on β amyloid protein aggregation and associated neuron damage and cognitive decline both in vitro and in vivo.
"Our goal is to complete these studies as soon as possible and publish our findings." At6 p.m. on the 14th, Rao Yi published "Review of Geng Meiyu and other responses to GV-971" on the personal public number "Rao-Yu".
reference: